<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03793660</url>
  </required_header>
  <id_info>
    <org_study_id>DAC-004-LITAR</org_study_id>
    <nct_id>NCT03793660</nct_id>
  </id_info>
  <brief_title>Biologic National Registry</brief_title>
  <acronym>BINAR</acronym>
  <official_title>Safety and Efficacy of Biotherapy in Rheumatoid Aarthritis and Spondyloarthritis. A Clinical Multicentric Study: Biologic National Registry (BINAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dacima Consulting</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ligue Tunisienne Anti Rhumatismale</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dacima Consulting</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BINAR is an open and multicentric Tunisian national registry performed by nearly 100
      rheumatologists
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BINAR is a Tunisian, descriptive, non-interventional, multicenter and prospective clinical
      study performed in rheumatology consultations, of both public and liberal sectors. Eligible
      patients are recruited by successive inclusions until the end of the recruitment period, set
      at one year. A Scientific Committee validates the scientific writing, a Steering Committee
      supervises the clinical operations of the project and a Data Review Committee supervises the
      management of the data and carries out all the missions of audit and control of validity of
      the collected data, as well as the planning of statistical analysis.

      Collected data are managed by the DACIMA Clinical Suite®, the electronic data capture
      platform which complies with the FDA 21 CFR part 11 requirements (Food and Drug
      Administration 21 Code of Federal Regulations part 11), the HIPAA specifications (Health
      Insurance Portability and Accountability Act), and the ICH standards (International
      Conference on Harmonisation).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2018</start_date>
  <completion_date type="Anticipated">May 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 23, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Safety assessment of biotherapy - Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Occurrence of infection or tuberculosis or death or neoplasia or any other treatment-related side effect of biotherapy</measure>
    <time_frame>Up to two years of follow-up</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] : occurrence of infection or tuberculosis or death or neoplasia or any other treatment-related side effect of biotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Rheumatoid Arthritis Activity</measure>
    <time_frame>At baseline and at two years follow-up</time_frame>
    <description>Number of patients with disease Activity Score (DAS) &lt; 2.6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire</measure>
    <time_frame>At baseline</time_frame>
    <description>HAQ assessment for Rheumatoid Arthritis patients (range score 0-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Spondylitis Fonctional Activity</measure>
    <time_frame>At baseline and at two years follow-up</time_frame>
    <description>Bath Ankylosing Spondylitis Fonctional Index measurement (BASFI) : (range score 0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Spondylitis Disease Activity</measure>
    <time_frame>At baseline and at two years follow-up</time_frame>
    <description>Bath Ankylosing Spondylitis Disease Activity Index measurement (BASDAI) : (range score 0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Spondylitis Activity</measure>
    <time_frame>At baseline and at two years follow-up</time_frame>
    <description>Number of patients with Ankylosing Spondylitis Disease Activity Score (ASDAS) &lt; 2.1</description>
  </secondary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <condition>Spondylitis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients treated with biologic for rheumatoid arthritis or spondylitis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Patient followed for rheumatoid arthritis according to ACR EULAR criteria or
             spondylitis including all disorders (axial, peripheral, enthesitis).

          -  Patient on biological treatment at the time of inclusion

          -  First biological treatment initiated ≤ 2 years

          -  Informed consent, read and signed

        Exclusion Criteria:

          -  Evolutionary neoplasia at the time of inclusion

          -  Other associated systemic diseases, except Sjögren's Syndrome

          -  Consent not obtained

          -  Pregnant or lactating woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir Kochbati, MD</last_name>
    <role>Study Chair</role>
    <affiliation>LITAR : Ligue Tunisienne Anti Rhumatismale</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kawther Ben Abdelghani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LITAR : Ligue Tunisienne Anti Rhumatismale</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samir Kochbati, MD</last_name>
    <phone>+21698307400</phone>
    <email>samirkochbati1@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rabie Razgallah, MD</last_name>
    <phone>+21620509729</phone>
    <email>r.razgallah@dacimasoftware.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rheumatology Department - Habib Thameur</name>
      <address>
        <city>Ben Arous</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Kochbati, MD</last_name>
      <email>samirkochbati1@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheumatology Department - HMPIT</name>
      <address>
        <city>Ben Arous</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Imène Gharsallah, MD</last_name>
      <email>imengharsallah@hotmail.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheumatology Department - Tahar Sfar</name>
      <address>
        <city>Mahdia</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Younes, MD</last_name>
      <email>mohamed.younes@rns.tn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheumatology Department - Institut Mohamed Kassab d'Orthopédie</name>
      <address>
        <city>Manouba</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Montassar Kchir, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheumatology Department - Fattouma Bourguiba</name>
      <address>
        <city>Monastir</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naceur Bergaoui, MD</last_name>
      <email>naceur.bergaoui@rns.tn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheumatology Department - Hédi Chaker</name>
      <address>
        <city>Sfax</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofiène Baklouti, MD</last_name>
      <email>sofien.baklouti@rns.tn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheumatology Department - Farhat Hached</name>
      <address>
        <city>Sousse</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyes Bouajina, MD</last_name>
      <email>elyes.bouajina@rns.tn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheumatology Department - Charles Nicolle</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leila Abdelmoula, MD</last_name>
      <email>leila_abdelmoula@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheumatology Department - La Rabta</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Eleuch, MD</last_name>
      <email>mohamed.elleuch@rns.tn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheumatology Department - Mongi Slim</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kawther Ben Abdelghani, MD</last_name>
      <phone>+216 26 333 739</phone>
      <email>kawther_ba@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Ahmed Laatar, MD</last_name>
      <email>laatar.ahmed@rns.tn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <link>
    <url>https://www.facebook.com/groups/1611044669000801/about/</url>
    <description>Social Media Group of the Project</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 29, 2018</study_first_submitted>
  <study_first_submitted_qc>January 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2019</study_first_posted>
  <last_update_submitted>July 4, 2019</last_update_submitted>
  <last_update_submitted_qc>July 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biologic</keyword>
  <keyword>Safety</keyword>
  <keyword>LITAR</keyword>
  <keyword>DACIMA</keyword>
  <keyword>Tunisia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

